Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer.
Joshua R HeyzaWen LeiDonovan WatzaHao ZhangWei ChenJessica B BackKendra L SchwartzGerold BeplerSteve M PatrickPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Our findings implicate p53 as a potential confounding variable in clinical assessments of ERCC1 as a platinum biomarker via promoting an environment in which error-prone mechanisms of ICL-R may be able to partially compensate for loss of ERCC1.See related commentary by Friboulet et al., p. 2369.